The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
To own Perpetua Resources, you have to believe the permitting and build-out of Stibnite can ultimately justify a high, pre-revenue valuation and years of reported losses. The new antimony pilot plant collaboration with Idaho National Laboratory and the U.S. Army reinforces the defense angle and could sharpen the story around critical minerals, but the immediate share price reaction suggests the stock was already pricing in a lot of optimism. In the near term, the key catalysts still look familiar: progress on permitting, clarity on long-term funding after the recent US$78.2 million raise, and any concrete steps toward offtake or federal backing for antimony. The biggest risks remain execution and financing, now with added complexity as Perpetua layers defense-spec processing ambitions on top of an already complex project.
However, one key risk here is not about geology at all, but about funding. Insights from our recent valuation report point to the potential overvaluation of Perpetua Resources shares in the market.Explore 7 other fair value estimates on Perpetua Resources - why the stock might be worth less than half the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com